Smital Shah

Smital Shah brings proven executive leadership expertise to her role as a board member of Graphite Bio, including over two decades of senior management experience in the biopharma and investment banking industries. She currently serves as chief business and financial officer of ProQR Therapeutics, a biotechnology company focused on rare genetic diseases. Previously, Ms. Shah managed the multi-billion-dollar debt, cash, and investment portfolios of Gilead Sciences. Her proven management and leadership experience in the biopharma industry is augmented by her earlier career in investment banking, where she has particular expertise in financial strategy, capital markets, and business development. Prior to Gilead, Ms. Shah spent several years in investment banking at Leerink Partners and J.P. Morgan focused on the biotech sector. Earlier in her career, she held various research and development positions at Johnson & Johnson. Ms. Shah is a board member and chair of the audit committee at Pliant Therapeutics.